Jump to content

Loteprednol

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by DePiep (talk | contribs) at 01:12, 18 December 2015 (Drugbox: use drug_name for title. reuse imagename, eg image caption or chemical data ('racemate') (via AWB script)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Loteprednol etabonate
Clinical data
AHFS/Drugs.comMicromedex Detailed Consumer Information
MedlinePlusa606003
ATC code
Legal status
Legal status
Identifiers
  • Chloromethyl 17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-17-carboxylate
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.167.120 Edit this at Wikidata
Chemical and physical data
FormulaC24H31ClO7
Molar mass466.951 g/mol g·mol−1
 ☒NcheckY (what is this?)  (verify)

Loteprednol (as the ester loteprednol etabonate) is a corticosteroid used in ophthalmology. Marketed by Bausch and Lomb as Lotemax in the U.S., ocular applications for this drug include the treatment of inflammation of the eye due to allergies (according to the prescription information sheet), as well as chronic forms of keratitis (e.g.: adenoviral and Thygeson’s keratitis), vernal keratoconjunctivitis, pingueculitis, and episcleritis. The drug has little or no effect on intraocular pressure.

See also

References

  • Steward, R; et al. (November 1998). "Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation". J Cataract Surg. 24: 1480–1489.
  • Pavesio, CE; Decory, HH (2008). "Treatment of ocular inflammatory conditions with loteprednol etabonate". Br J Ophthalmol. 92 (4): 455–459. doi:10.1136/bjo.2007.132621. PMID 18245274.



Español